KOL Perspectives: Biomarker Potential of Type I IFN Gene Signature in Lupus

Market: Pharmaceuticals and Healthcare

Global, 32 pages report, published by GlobalData

Report ThumbnailJanuary-2018
KOL Perspectives: Biomarker Potential of Type I IFN Gene Signature in Lupus

Summary

This KOL Insight briefing focuses on the IFN gene signature as a potential biomarker in Lupus.

The briefing includes analysis of KOL opinion on the following topic areas -
- Awareness of biomarkers and predictors of disease activity in lupus
- Usefulness of the type I IFN signature test to identify patients who are most likely to respond to IFN-targeting therapies
- Impact of availability of a biomarker on wi

Read More
  • Table of Contents
  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Read More

Please select a license type

Share

Related Products

GlobalDataKOL Perspectives: Biomarker Potential of Type I IFN Gene Signature in LupusProduct ThumbnailKOL Perspectives: Biomarker Potential of Type I IFN Gene Signature in Lupus, Industry ReportProduct #: 1190964
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2019 Global Market Analyst. All Rights Reserved